Your browser doesn't support javascript.
loading
Diagnostic impact of F-FDG PET/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy
Tatar, Gamze; Alçin, Göksel; Sengul Samanci, Nilay; Erol Fenercioglu, Özge; Beyhan, Ediz; Fikret Cermik, Tevfik.
Afiliación
  • Tatar, Gamze; Istanbul Bagcılar Training and Research Hospital. Bagcılar. Turkey
  • Alçin, Göksel; Istanbul Training and Research Hospital. Istanbul. Turkey
  • Sengul Samanci, Nilay; Istanbul Training and Research Hospital. Istanbul. Turkey
  • Erol Fenercioglu, Özge; Istanbul Training and Research Hospital. Istanbul. Turkey
  • Beyhan, Ediz; Istanbul Training and Research Hospital. Istanbul. Turkey
  • Fikret Cermik, Tevfik; Istanbul Training and Research Hospital. Istanbul. Turkey
Clin. transl. oncol. (Print) ; 24(10): 1903–1913, octubre 2022. ilus
Artículo en Inglés | IBECS | ID: ibc-207946
Biblioteca responsable: ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT

Introduction:

Immunotherapy is an effective treatment method for cancer cells with humoral and cellular immune mechanisms of action but triggers an inflammatory response and disrupts standard protective immune tolerance. Early detection of immune-related adverse events (irAEs) on PET/CT is crucial for patient management and subsequent therapy decisions. In this study, we aimed to evaluate the impact of 18F-FDG PET/CT on detecting of irAEs in patients receiving immunotherapy.Patients and methodsForty-six patients with advanced RCC (n 32), malign melanoma (n 9), lung cancer (n 4), and laryngeal carcinoma (n 1), who underwent 18F-FDG PET/CT imaging for response assessment after immunotherapy, were enrolled in the study. Newly detected findings associated with irAEs on posttreatment PET/CT images were compared with the pretreatment PET/CT, both qualitatively and semi-quantitatively.ResultsTwenty-eight (61%) patients developed irAEs as observed on PET/CT. Enteritis/colitis was the most frequent irAE visualized on PET/CT with 13 patients (28.2%), followed by gastritis (17.3%), thyroiditis (13%), and myositis/arthritis (13%). Hepatitis (6.5%), pneumonitis (6.5%), sarcoid-like reaction (4.3%), and hypophysitis (4.3%) were observed to a lesser extent. The median time between the appearance of irAEs on PET/CT and the initiation of immunotherapy was 4.3 months. There were no significant differences in age, sex, and treatment response status of patients with and without irAEs.Conclusion18F-FDG PET/CT plays a fundamental role in cancer immunotherapy with the potential to show significant irAEs both in the diagnosis and in follow-up of irAEs. IrAEs were present on PET/CT images of more than half of the patients who received immunotherapy in our study. (AU)
Asunto(s)

Buscar en Google
Colección: Bases de datos nacionales / España Base de datos: IBECS Asunto principal: Fluorodesoxiglucosa F18 / Tomografía de Emisión de Positrones / Inmunoterapia / Melanoma Límite: Humanos Idioma: Inglés Revista: Clin. transl. oncol. (Print) Año: 2022 Tipo del documento: Artículo Institución/País de afiliación: Istanbul Bagcılar Training and Research Hospital/Turkey / Istanbul Training and Research Hospital/Turkey
Buscar en Google
Colección: Bases de datos nacionales / España Base de datos: IBECS Asunto principal: Fluorodesoxiglucosa F18 / Tomografía de Emisión de Positrones / Inmunoterapia / Melanoma Límite: Humanos Idioma: Inglés Revista: Clin. transl. oncol. (Print) Año: 2022 Tipo del documento: Artículo Institución/País de afiliación: Istanbul Bagcılar Training and Research Hospital/Turkey / Istanbul Training and Research Hospital/Turkey
...